Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA7 | P43166 | 6/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.38 |
| ▸ | CA5A | P35218 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA6 | P23280 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18993721 | 0.87 | PDE4D (0.62) | PDE4DPDE3ACISD1POLBRAB9A | |
| SCHEMBL231240 | 0.86 | PDE4D (0.61) | PDE4DPDE3ACISD1POLBLMNA | |
| SCHEMBL230673 | 0.85 | PDE4D (0.58) | PDE4DPDE3ACISD1POLBCA1 | |
| SCHEMBL16581034 | 0.85 | PDE4D (0.58) | PDE4DPDE3ACISD1POLBCA1 | |
| SCHEMBL230303 | 0.83 | PDE4D (0.58) | PDE4DPDE3ACISD1POLBCA1 | |
| SCHEMBL230505 | 0.83 | PDE4D (0.54) | PDE4DPDE3ACISD1POLBLMNA | |
| SCHEMBL231445 | 0.83 | PDE4D (0.53) | PDE4DPDE3ACISD1POLBF2 | |
| SCHEMBL29436060 | 0.83 | PDE4D (0.53) | PDE4DPDE3ACISD1POLBF2 | |
| SCHEMBL5540719 | 0.81 | PDE4D (0.55) | PDE4DPDE3ACISD1POLBLMNA | |
| SCHEMBL12522803 | 0.80 | PDE4D (0.56) | PDE4DPDE3ACISD1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | PDE4D 597/4885PDE3A 441/4885CISD1 3887/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | PDE4D 855/4885PDE3A 416/4885CISD1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.